Sales and Use Tax in Healthcare and Medical Products: Common Exposure Areas
The medical products sector covers a vast array of products and services, making compliance a complicated undertaking at the best of times. For life sciences startups (and companies at any growth stage, for that matter), this introduces many challenges, not the least of which is financial, tax, and compliance exposure.
For California medical products companies, it’s critical to understand exposure areas, as any missteps in terms of tax treatment, revenue recognition, or regulatory alignment can lead to missed opportunities, operational inefficiencies, and audits.
With the right planning and systems in place, companies can reduce these risks and ensure they don’t miss out on any incentives.
What You Need to Know About Regulatory Classification
How a company’s medical products are classified (Class I, II, or III) can have a direct influence on financial and tax issues. Higher classifications correlate to risk and, as such, have longer development and approval timelines, higher costs, and more complex commercialization strategies.
Classification can also affect how related expenses are treated, i.e., whether they are deductible immediately or capitalized and amortized over time. A Class III device will likely have longer development and regulatory cycles, underscoring the need for improved financial planning and cash-flow forecasting.
Accurate classification also helps you identify tax credits the activity may be eligible for, like state and federal R&D credits. If classification is misaligned, the company may miss out on credits and risk exposure during an audit.
Potential Exposure Areas in MedTech
R&D Exposure
Early-stage MedTech companies typically spend heavily on R&D. From a tax standpoint, these expenses are under the most scrutiny, as they must comply with stringent regulations to qualify for tax credits.
Proper documentation is vital here, as without adequate records detailing the research activity, its technical uncertainty, development process, and the overall purpose, credits could be disallowed.
Under IRS Section 174, some expenses must be capitalized while others can be deducted immediately. Timing and other details, such as whether the research takes place in the U.S. or abroad, can affect cash flow and financial planning.
California has a state-level R&D credit, but the rules and thresholds differ, making it challenging for organizations to ensure they get the most out of the benefit while staying compliant.
Supply Chain and Manufacturing Exposure
Manufacturing introduces additional complexities that typically arise once the company begins commercializing and scaling up.
Exemptions may apply to some equipment, purchases, raw materials, and occasionally to prototyping inputs, but finding out which items are exempt for research and development purposes can be challenging in itself. Ultimately, it’s in a company’s best interest to understand the nuances, as it can provide exposure across multiple stages of production.
Tax implications can also arise from decisions to contract-manufacture or keep it in-house. Contracted manufacturing may occur in multiple states, triggering nexus and additional filing requirements. International supply chains add another layer of complexity, as transfer pricing and agreements between companies and contractors must be structured to withstand regulatory and tax scrutiny.
Another common exposure area is inventory accounting. Medical devices are prone to technical obsolescence following regulatory changes, upgrades, or product iterations, underscoring the need for accurate valuations and documentation.
Revenue Recognition
Compared to other life sciences niches, MedTech is relatively straightforward in terms of revenue. Hardware, software, and ongoing services are common, and each represents a revenue stream.
ASC 606 lays out the accounting principles that govern how and when companies recognize revenue. Part of this rule mandates the articulation of performance obligations and the allocation of the corresponding revenue, which may involve chargebacks, discounts, and rebates, all of which must be reasonably anticipated and recorded.
Financial reporting and tax timing are affected, and inaccuracy can be challenged through restatements or audits.
Sales Tax and Economic Nexus Exposure
As companies expand, sales tax can become more complex. California, in particular, has unique rules regarding the taxation of medical devices and related products. Exemptions may apply in some cases, such as for devices that require a prescription, but improper classification can reverse these benefits.
Sales tax audits are all too common, especially for companies experiencing rapid growth. Without robust compliance systems in place, exposure can occur unintentionally, taking focus away from the day-to-day.
It’s common for MedTech companies to operate across multiple states, which can establish an economic nexus. Even without a physical presence, like an office, sales activities across state lines can trigger multi-state tax and compliance requirements.
Working with an accounting firm experienced in medical devices and life sciences will ensure you have the systems in place to track nexus-causing activities, so they can be factored into financial planning.
International and Cross-Border Expansion
Tax exposure increases drastically as soon as a company expands internationally. Value-added tax (VAT), goods and services tax (GST), or harmonized sales tax (HST) can apply in foreign countries and may require new registrations and tax reporting.
We must also consider import and export duties, which will undoubtedly apply to medical devices, no matter where they are distributed.
Transfer pricing becomes an issue when IP, manufacturing, or distribution happens in multiple regions. Besides noncompliance and penalties, failing to record or document these activities properly can lead to double taxation. Good planning and organization now will help you avoid the inevitable cleanup and restructuring later.
The Importance of Strong Documentation
Documentation is the foundation of compliance in just about every aspect of business. Bear in mind that life sciences companies are often audited because of the complexities of their R&D activities, large tax credit claims, inconsistent revenue, and rapid cross-border growth.
Keeping your financials clean and up-to-date is the best way to beat the auditors at their own game. Clearly articulated accounting practices and robust documentation can reduce the risk and support accurate forecasting.
In best practice:
Track and document all R&D activities
Document detailed cost allocations
Maintain consistent revenue recognition protocols
Apply capitalization rules accurately
Claim all R&D credits you are eligible for
The MedTech experts at Growise understand your challenges and can help you establish compliant systems and strategies aligned to your growth stage and future plans. We can help you make sense of complex systems, avoid costly mistakes, and enable the tax savings and growth you imagine. Set up a call today, and let’s get to work.